A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer

Inclusion Criteria: * Histologically or cytologically confirmed advanced pancreatic cancer * Locally advanced pancreatic cancer is defined as the presence of a surgically unresectable tumor(involving the celiac axis or the superior mesenteric artery) * Performance Status:0-1(ECOG) * Patients of age =\>20 and 75\> * White Blood Cell (WBC) \>=3,500/mm3,12,000/mm3, * Neutrophils \>=1,500/mm3, platelets=100,000/mm3, * Hemoglobin \>=9.5 g/dl, * GOT \</=2.0 X Upper Limit Number (ULN), * Glutamate Pyruvate Transaminase (GPT) \</=2.0 X ULN, * Alkaline Phosphatase (ALP) \</=2.0 X ULN, * Total bilirubin \<=1.5mg/dl, * Serum creatinine \<=1.2mg/dl, * Creatinine clearance\>=50 ml/min * arterial O2 pressure (PaO2) \>=70torr or arterial O2 saturation (SpO2) \>=96% * Life expectancy more than 3 months. * Written informed consent. Exclusion Criteria: * Active infection * Lung fibrosis or intestinal pneumonia detectable on chest X-ray and CT * Severe complication (heart disease, cirrhosis, diabetes) * Myocardial infarction within 3 months * Active synchronous or metachronous malignancy * Pregnant or lactation women, or women with known or suspected pregnancy * Symptomatic brain metastasis * History of severe drug allergy * Peripheral neuropathy * Patients who are judged inappropriate for the entry into the study by the investigator